Event

COVID-19: State of the art 2022 – DRAGON IMI project

10 November, 2022 | Online
09:00-16:30 CET

Watch live: Follow this link to access the live event

Information: ERS Statement on COVID-19 and upcoming ERS events

A virtual event dedicated to COVID-19, where top level faculty will share the latest advances, data and best practices related to SARS-CoV-2 and COVID-19, and discuss currently unmet needs and solutions.

This event is part of the EU-funded DRAGON project and follows up on two past events: the April 2021 COVID-19: State of the Art and February 2022 webinar Panel discussion on long COVID.

Target audience:

  • DRAGON consortium members
  • Clinicians, scientists, healthcare professionals, allied healthcare professionals, rehabilitation specialists, general practitioners
  • Epidemiologists
  • Data scientists
  • Public health representatives
  • Radiologists
  • Patient organisations

Background

The DRAGON project is coordinated by the University of Maastricht with Radiomics as the Project Lead, and partners comprised of high-tech small and medium-sized enterprises (SMEs), academic research institutes, biotechnology and pharmacological partners, and ELF and ERS. Funded by the Innovative Medicines Initiative (IMI), it will use AI and machine learning to deliver a patient-centred decision support system that will enable stakeholders to participate in the development of rapid precise diagnosis and prognosis.

“The application of digital imaging together with clinical data to inform clinical decisions through artificial intelligence is very exciting.  The DRAGON project offers to do this as part of our response to the pandemic.” Professor Christopher Brightling, event co-chair

CME credits

This course has been accredited by the European Board for Accreditation in Pneumology (EBAP) with 5.5 CME credits covering the whole programme. CME credits will be granted upon attendance of at least 30 minutes during the live event only, with 0.5 CME credits per 30 minutes of attendance.

The morning part (09:00-13:00 CET) will consist of keynote talks, short lectures, interactive discussion and Q&A time. Sessions will focus on the following three topics:

  • Epidemiology
  • Pathophysiology
  • Management

Each topic will be discussed from three different aspects: 1) acute COVID, 2) long COVID, 3) acute and long COVID in children.

The afternoon part (14:00-16:30 CET) will be an interactive scenario-planning workshop “How can we do better for the next pandemic?” Participants will choose one of four breakout groups, each focusing on a specific scenario. Facilitators of each breakout group will encourage participants to share their experiences to develop worst-case scenarios and then suggest ideas on how the whole research and healthcare community can work together to avoid them. To better plan the capacities of the workshop, please let us know, which breakout group you plan to attend in this link.

View the full, detailed programme below:

Access the virtual programme

Chairs

Christopher Brightling - profile image
Christopher Brightling
United Kingdom

Professor Christopher Brightling is Senior Investigator at the National Institute for Health Research (NIHR), Clinical Professor in Respiratory Medicine, Chair of the ERS Science Council and founding Director of the ERS Clinical Research Collaborations. His research focuses on improving the clinical management, and understanding the immunopathogenesis of asthma, chronic cough and COPD.

He has published over 370 peer-reviewed articles, has an h-index of 95, and is a member of the American College of Chest Physicians’ Cough Guidelines, the British Thoracic Society, the American Thoracic Society/European Respiratory Society Severe Asthma guidelines and the scientific committee for the Global INitiative for Asthma - GINA.


Declaration of Interests

Declaration of Interests of

1 - Personal interests

Regular Paid Consultancy Work

None

Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000
Eva Polverino - profile image
Eva Polverino
Spain

Dr Eva Polverino is a pulmonology expert in respiratory infections. She is Senior Researcher at the Vall D’Hebron Institute of Research (VHIR) in Barcelona, Spain and Head of ERS Assembly 10; ‘Respiratory Infections’.

Dr Polverino graduated from the medical School of the Second University of Naples (SUN) in 1999 and obtained her doctorate from the University of Pisa in 2002. She also holds a master’s degree in the management of Clinical Units from the University of Murcia.


Declaration of Interests

Declaration of Interests of

1 - Personal interests

Regular Paid Consultancy Work

None

Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000

Organising committee

Stefano Aliberti - profile image
Stefano Aliberti
Italy

Stefano Aliberti is Professor of Respiratory Medicine at the University of Milan, Italy, a member of the ERS Clinical Research Collaboration working group, and a former ERS Curriculum Development Director, who has also collaborated in the writing of the ERS Guidelines for the management of adult bronchiectasis.

He graduated with honours from the University of Milan’s School of Medicine in 2003, before completing a Fellowship in Pulmonary and Critical Care Medicine at the university’s Institute of Respiratory Diseases. After that, he completed a Clinical Research Fellowship in Pulmonary Medicine at his alma mater, and from 2006 to 2007, he was a clinical research fellow at the Division of Infectious Diseases of the Internal Medicine Department of the University of Louisville in the United States.

Professor Aliberti is the co-author of more than 50 scientific articles and book chapters, and has delivered dozens of lectures at national and international events as well as courses at university and master’s degree level. Because of his scientific work, Professor Aliberti was laureated with the 2007 ERS Young Researcher Award.


Declaration of Interests

Declaration of Interests of

1 - Personal interests

Regular Paid Consultancy Work

None

Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000
James Chalmers - profile image
James Chalmers
United Kingdom

James Chalmers is Professor of Respiratory Medicine at the University of Dundee and a consultant physician. Graduating from the University of Glasgow’s School of Medicine, he has since gone on to obtain a doctorate from the University of Edinburgh,
and is now a member of Edinburgh’s Royal College of Physicians.

He has published more than 200 peer reviewed papers, chairs the European Bronchiectasis Registry, and serves regularly as a reviewer for each of the major respiratory medicine journals (American Journal of Respiratory and Critical Care Medicine, Thorax, European Respiratory Journal, Chest, Respiratory Medicine).

His research operates at both translating basic discoveries into therapies, and translating therapies into clinical practice, and has deliberately focussed on areas of perceived need in respiratory medicine, with high morbidity and mortality but limited investment in research.


Declaration of Interests

Declaration of Interests of

1 - Personal interests

Regular Paid Consultancy Work

None

Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000
Marko Topalović - profile image
Marko Topalović
Belgium
CEO of ArtiQ

Marko Topalović PhD is a CEO of ArtiQ (Leuven, Belgium); a company that aims to empower medical professionals with artificial intelligence to accurately and timely diagnose, treat and monitor patients with lung diseases.

Formerly, as a postdoctoral researcher in the University Hospital in Leuven (Belgium), Marko worked on inventing algorithms for assessing lung disease. He obtained a PhD degree on the topic “Artificial intelligence for pulmonary function tests” at the KU Leuven.

His scientific work has contributed to many peer-reviewed publications and numerous conference presentations. Moreover, he received several international awards.


Declaration of Interests
Scott Wagers - profile image
Scott Wagers
Belgium
Founder and CEO of BioSci Consulting

Dr Scott Wagers trained as a respiratory and critical care physician and researcher, and brings more than 20 years’ experience in the life sciences, with more than 10,000 hours of experience as a moderator of dialogue in cognitively diverse teams.

As the founder and CEO of BioSci Consulting, he has had a pivotal role in several European based collaborative research projects (U-BIOPRED, AirPROM, COPD MAP, eTRIKS, ERS Research Agency, AIMS-2-Trials).

His main focus is on bringing innovative companies together with stakeholders and diverse disciplines to develop and deliver collaborative projects that will help change the future of medicine.


Declaration of Interests

Declaration of Interests of

1 - Personal interests

Regular Paid Consultancy Work

None

Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000
Sara Tomassetti - profile image
Sara Tomassetti
Italy

Sara Tomassetti is currently Associate Professor of Respiratory Medicine at Florence University, Italy, and Head of Interventional Pulmonology Unit at Careggi University Hospital, Florence, Italy.

She has extensive clinical and research experience in interstitial lung diseases and interventional pulmonology.
She is a faculty member of the European Respiratory Society, member of the ERS guidelines task force, BOND National member for Italy of the European Association for Bronchology and Interventional Pulmonology and member of the executive committee of the Italian Thoracic Society (AIPO-ITS). From a clinical research perspective, she has been the primary investigator (PI) of several sponsored and investigator initiated clinical trials on diagnosis and treatment of interstitial lung diseases and idiopathic pulmonary fibrosis. She publishes on clinical research aspects of interstitial lung diseases and interventional pulmonology. She regularly reviews research and clinical manuscripts for international journals.


Declaration of Interests
Wim Vos - profile image
Wim Vos
Belgium
CEO at Radiomics

Wim serves as the CEO at Radiomics. He is the driver behind Radiomics’ vision, which is based on his knowledge gained in over 15 years in different leadership roles in quantitative imaging companies.

Before joining Radiomics in 2019 Wim was co-founder of FLUIDDA where he initially led the technical development team and was afterwards responsible for the global commercial activities. He holds a MSc in aerospace engineering from TU Delft (NL) and a PhD in physics from the university of Antwerp (BE).


Declaration of Interests

Declaration of Interests of

1 - Personal interests

Regular Paid Consultancy Work

None

Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000
Sebastiaan Huntjens - profile image
Sebastiaan Huntjens
Belgium
Project Manager at Radiomics

Sebastiaan Huntjens is a health policy, economics, and organization specialist with a broad knowledge in funding acquisition for R&D, grant writing and grant management.

His focus is on connecting innovations in the field of radiomics, decision support tooling and the use of artificial intelligence with company opportunities. His goal is to bring together scientific discoveries, innovative new approaches to personalized medicine and help create future medicine together with academia, industry, and stakeholder communities. Sebastiaan is involved in many European Collaborative projects in this field such as DRAGON, EUCANIMAGE and EUCAIM.


Declaration of Interests
Janne Vignero - profile image
Janne Vignero
Belgium

Janne Vignero is a medical physicist and obtained a PhD in X-ray physics in 2018. Currently, she works as a post-doctoral researcher at the Radiology department of the university hospital of Leuven, Belgium, where she tries to make the bridge between technical research and clinic. With a background in physics and experience in medical imaging, she collaborates with radiologists to bring deep learning and data science into clinical practice.


Declaration of Interests
Ruud van der Made - profile image
Ruud van der Made
Netherlands
Patient

Ruud van der Made is a member of the COVID-19 Patient Advisory Group and a COVID-19 patient. He cares for his wife (also having survived COVID-19) who has Lymphangioleiomyomatosis.


Declaration of Interests

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101005122. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.